SCHEMBL417009

SCHEMBL417009

O=C(O)COc1cccc(C23CC4CC(CC(C4)C2)C3)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
HIF1A Q16665 8/20 0.51
EPAS1 Q99814 6/20 0.51
LMNA P02545 3/20 0.50
ALOX15 P16050 2/20 0.47
MAPK1 P28482 2/20 0.45
NPC1 O15118 1/20 0.45
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PTPN7 P35236 1/20 0.44
CASP2 P42575 1/20 0.44
FAAH O00519 1/20 0.44
CNR2 P34972 1/20 0.44
MDH1 P40925 1/20 0.43
MDH2 P40926 1/20 0.43
EP300 Q09472 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083023 0.82 MEN1 (0.76) RAB9AMEN1KMT2AHIF1AEPAS1
SCHEMBL421046 0.82 MEN1 (0.76) RAB9AMEN1KMT2AHIF1AEPAS1
SCHEMBL178216 0.80 MEN1 (0.43) RAB9AMEN1KMT2AHIF1AEPAS1
SCHEMBL13216108 0.79 HSD11B1 (0.65) MEN1KMT2ALMNAALOX15TSHR
SCHEMBL419735 0.76 SMN1; SMN2 (0.47) RAB9AMEN1KMT2AHIF1AEPAS1
SCHEMBL420870 0.76 SERPINE1 (0.66) RAB9AHIF1AEPAS1NPC1L3MBTL1
SCHEMBL29896966 0.76 SERPINE1 (0.66) RAB9AHIF1AEPAS1NPC1L3MBTL1
SCHEMBL28278040 0.76 GRIN1 (0.51) RAB9AMEN1KMT2AHIF1AEPAS1
SCHEMBL14829333 0.76 TDP1 (0.55) RAB9AMEN1KMT2AHIF1AEPAS1
SCHEMBL14829799 0.76 KMT2A (0.48) RAB9AMEN1KMT2AHIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 RAB9A 2650/4885MEN1 844/4885KMT2A 4433/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 RAB9A 2650/4885MEN1 844/4885KMT2A 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.